Open AccessImplantable Cardioverter-Defibrillators in Patients with ESRD: Complications, Management, and Literature Review
Author(s) -
Mehdi Bayati,
Kaveh Hosseini,
Vasheghani-Farahani Ali
Publication year - 2019
Publication title -
current cardiology reviews
Language(s) - English
Resource type - Journals
eISSN - 1875-6557
pISSN - 1573-403X
DOI - 10.2174/1573403x15666190118123754
Subject(s) - medicine , dialysis , sudden cardiac death , intensive care medicine , implantable cardioverter defibrillator , end stage renal disease , disease , pneumothorax , dialysis catheter , cardiac resynchronization therapy , heart failure , surgery , ejection fraction
Cardiovascular diseases are the leading cause of death among dialysis patients, accounting for about 40% of all their mortalities. Sudden cardiac death (SCD) is culpable for 37.5% of all deaths among patients with end-stage renal disease (ESRD). Implantable cardioverterdefibrillators (ICDs) should be considered in dialysis patients for the primary or secondary prevention of SCD. Recent studies on the implementation of ICD/cardiac resynchronization therapy do not exclude patients with ESRD; however, individualized decisions should be made in this group of patients. A thorough evaluation of the benefits of ICD implementation in patients with ESRD requires several large-scale mortality studies to compare and follow up patients with ESRD with and without ICDs. In the present study, we sought to determine and clarify the complications associated with ICD implementation and management thereof in patients suffering from ESRD.